TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02548572

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcorneal Electrical Stimulation using Okustim device
Description: The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal Electrical Stimulation using Okustim device
Description: The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device).
Study: NCT01782456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Oral Nutritional Supplement
Description: Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
Study: NCT00813449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine plus Endostar (Experimental group)
Description: dacarbazine plus Endostar

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dacarbazine plus placebo (control group)
Description: dacarbazine plus placebo
Study: NCT00783133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: Allegra 180 mg daily x 7 days
Study: NCT03678779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Video-based brief nutrition education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined
Description: Both Incentive and Education interventions received
Study: NCT02582918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach with patient education and patient navigation services
Description: * Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~* Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~* If results are normal, the patient is invited to repeat screening in 6 months.~* If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~* If CT/MRI is unremarkable, the patient is referred back for routine screening.~* If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~* All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic.
Study: NCT00783133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: Allegra 180 mg daily x 7 days
Study: NCT01372124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
Study: NCT03580564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Study: NCT00888784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Cyanoacrylate injection
Description: Endoscopic Cyanoacrylate injection in gastric varix

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: beta-blocker (propranolol)
Description: Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
Study: NCT02826291

Intervention type: DEVICE
Intervention: RD-100i, OSNA
Description: quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
Study: NCT04380675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music listening during ESWL
Study: NCT02645344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Cueing (SC)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Study: NCT02780167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 10 mg of PF-04965842 QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 30 mg of PF-04965842 QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 100 mg of PF-04965842 QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 200 mg of PF-04965842 QD for 12 weeks
Study: NCT02376517

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
Study: NCT05283616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim 3mg per chemotherapy cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim 3mg per chemotherapy cycle
Study: NCT04608955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-081
Description: WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-081
Description: WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-081
Description: WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-081
Description: WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline
Description: This licensed drug will be used in arm F as positive comparator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-drug background treatment (MBT)
Description: MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-drug background treatment (MBT)
Description: MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
Study: NCT04352803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose MSC's
Description: Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
Study: NCT03612882

Intervention type: OTHER
Intervention: Online questionnaire
Description: Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
Study: NCT00354640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 milligram tablet PO QD for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 40 milligram tablet PO QD for 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: laboratory analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: laboratory analysis
Study: NCT01772420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag Olamine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag Olamine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01240837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arenga Pinnata Sugar
Description: 50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
Study: NCT02894151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot medroxyprogesterone acetate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Study: NCT00590707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deeper sedation
Description: The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate sedation
Description: The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
Study: NCT01982136

Intervention type: PROCEDURE
Intervention: end-to-end urethroplasty

Intervention type: PROCEDURE
Intervention: substitution urethroplasty (buccal mucosa)

Intervention type: PROCEDURE
Intervention: substitution urethroplasty (pedicled skin flap)
Study: NCT02891278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside
Description: Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation
Description: Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
Study: NCT02662855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WHO-recommended therapies
Description: symptomatic and supportive treatments according to the WHO manual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO-recommended therapies
Description: symptomatic and supportive treatments according to the WHO manual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: oral administration of Favipiravir tablets
Study: NCT05345119

Intervention type: DRUG
Intervention: Sirolimus
Description: 2 mg orally on the first day followed by 0.5 mg per day for 12 weeks

Intervention type: DRUG
Intervention: Methylprednisolone
Description: 500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
Study: NCT03416842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with 4D Motion Capture Device
Description: Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
Study: NCT04195568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surpass Evolve Flow Diverter System
Description: The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
Study: NCT04255888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laterally positioned flap in thick periodontal phenotype.
Description: Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laterally positioned flap in thin periodontal phenotype.
Description: Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
Study: NCT04215406

Intervention type: OTHER
Intervention: The level of air pollution
Description: The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.
Study: NCT00813904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rThrombin, 1000 IU/mL
Description: At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
Study: NCT01189513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900105
Description: 10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
Study: NCT01231568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
Study: NCT02780167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD for 12 weeks
Study: NCT01231568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen C
Description: Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
Study: NCT03400059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chordate System S211 in treatment mode
Description: Chordate System S211 in treatment mode

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Chordate System S211 in placebo mode
Description: Chordate System S211 in placebo mode
Study: NCT05500573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sperm Sorting
Description: Selection of gender specific spermatozoa using a multilayer density gradient solution
Study: NCT04272476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture and moxibustion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Study: NCT01231568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen C
Description: Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen D
Description: Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
Study: NCT01844531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: single tablet empagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin (Glucophage®)
Description: single tablet metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin (Glucophage®)
Description: single tablet metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: single tablet empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin and metformin
Description: FDC tablet empagliflozin and metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin and metformin
Description: FDC tablet empagliflozin and metformin
Study: NCT05604079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolarynx
Description: The device transmits electronic sound source vibrations through soft tissue, either the neck at the level of the glottis, or less commonly the check. Speech is created through movements of articulators including the lips, tongue and jaw.
Study: NCT01231568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen D
Description: Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
Study: NCT04686942

Intervention type: DIAGNOSTIC_TEST
Intervention: After sonazoid
Description: 0.015ml/mg sonazoid enhanced US to detection of liver metastases.
Study: NCT01596946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact tracing mode test at clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-sampling at home - Sent Test Kit
Study: NCT03703518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed reality
Description: This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise group
Description: This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
Study: NCT02083029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulated dive reflex
Description: All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulated dive reflex
Description: All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulated dive reflex
Description: All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
Study: NCT04186546

Intervention type: DEVICE
Intervention: Zephyr Valve Procedure
Description: The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
Study: NCT02864238

Intervention type: OTHER
Intervention: electronic milestone pathway
Description: an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
Study: NCT01023490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 34,5000 IU vitamin D per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo